In this episode, Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, discuss key data supporting contemporary dosing strategies with the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:

• Individualizing therapy
• Clinical data and experience informing optimal dosing
• Key adverse events

Presenters:

Kanwal Raghav, MD, MBBS
Associate Professor, Gastrointestinal Medical Oncology 
The University of Texas MD Anderson Cancer Center
Houston, Texas

Rachel Riechelmann, MD, PhD
Head, Clinical Oncology Department
Medical Oncologist
AC Camargo Cancer Center 
Sao Paulo, Brazil 

Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Link to full program: 
https://bit.ly/3aVXplL

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.